EPRX
Eupraxia PharmaceuticalsEPRX
EPRX
$2.80
1.45%
Market Cap: $99.7M
About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
Employees: 21
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4.85% more ownership
Funds ownership: 0% [Q1] → 4.85% (+4.85%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for EPRX.
Financial journalist opinion
Based on 3 articles about EPRX published over the past 30 days